Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1292539 | 0.85 | PIK3CD (0.43) | PIK3CDMEN1KMT2ACA2 | |
| SCHEMBL9466 | 0.84 | ALDH1A1 (0.33) | — | |
| SCHEMBL8958 | 0.84 | PIK3CD (0.33) | PIK3CDMEN1KMT2A | |
| SCHEMBL11793063 | 0.82 | PIK3CD (0.42) | PIK3CDMEN1KMT2ACA2 | |
| SCHEMBL15745725 | 0.82 | PIK3CD (0.42) | PIK3CDMEN1KMT2ACA2 | |
| SCHEMBL23254163 | 0.78 | PIK3CD (0.36) | PIK3CDMEN1KMT2A | |
| SCHEMBL4375598 | 0.76 | — | — | |
| SCHEMBL3429383 | 0.75 | — | — | |
| SCHEMBL6521475 | 0.74 | LMNA (0.31) | — | |
| SCHEMBL13925694 | 0.74 | PIK3CD (0.37) | PIK3CDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048844-B1 | Preventing airway mucus production by administration of EGF-R antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-01 | — | — | US | claimed |
| WO-2009103719-A1 | SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND USE AND PRODUCTION THEREOF | FREIE UNIVERSITÄT BERLIN (DE) | 2009-08-27 | — | — | WO | claimed |
| US-7358222-B2 | Preventing airway mucus production by administration of EGF-R antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-15 | — | — | US | claimed |
| EP-1846396-A2 | SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND THEIR USE | Freie Universität Berlin (DE) | 2007-10-24 | — | — | EP | claimed |
| US-7132427-B2 | Quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | claimed |
| WO-2006084882-A2 | SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND THEIR USE | FREIE UNIVERSITÄT BERLIN (DE) | 2006-08-17 | — | — | WO | claimed |
| EP-1408980-A4 | NOVEL QUINAZOLINES AND USES THEREOF | ARIAD PHARMA INC (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1408980-A2 | NOVEL QUINAZOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030100573-A1 | Novel quinazolines and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2003-05-29 | — | — | US | claimed |
| WO-2003000188-A2 | NOVEL QUINAZOLINES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
| EP-0823900-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-12-27 | — | — | EP | claimed |
| US-5770599-A | RECEPTOR TYROSINE KINASE INHIBITORS including 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(2-morpholinoethoxy)quinazoline (gefitinib) | ZENECA LIMITED (GB) | 1998-06-23 | — | — | US | claimed |
| EP-0823900-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | claimed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | claimed |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2013-01-03 | — | — | US | disclosed |
| WO-2011112588-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2009103719-A1 | SUBSTITUTED 4-(INDOL-3-YL)QUINAZOLINES AND USE AND PRODUCTION THEREOF | FREIE UNIVERSITÄT BERLIN (DE) | 2009-08-27 | — | — | WO | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100573-A1 | Novel quinazolines and uses thereof | UQCRB, NQO2, RAB7A | PIK3CD 4480/4885MEN1 1698/4885KMT2A 3762/4885 |
| US-20130005726-A1 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS | NOD2, RIPK2, RIPK1 | PIK3CD 1345/4885MEN1 3207/4885KMT2A 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.